Global iPSC-Derived Cell Therapy Supply, Demand and Key Producers, 2026-2032
The global iPSC-Derived Cell Therapy market size is expected to reach $ 22604 million by 2032, rising at a market growth of 11.2% CAGR during the forecast period (2026-2032).
iPSC-Derived Cell Therapy refers to living cell therapeutic products manufactured from induced pluripotent stem cells (iPSCs) through processes including directed differentiation, purification, expansion, genetic engineering, and quality release testing. These products encompass multiple cell types such as NK/T immune cells, neural progenitor cells, cardiomyocytes, pancreatic islet cells, retinal cells, and mesenchymal stromal cells. They are being developed for applications in oncology, Parkinson?s disease, heart failure, diabetes, retinal degenerative diseases, and inflammatory tissue repair. The platform emphasizes lineage consistency, genomic stability, control of residual undifferentiated cells, immune matching strategies, cryopreserved formulation, and clinical-grade GMP scalable manufacturing capabilities. The overall gross margin is approximately 65%.
Demand for iPSC-derived cell therapies is primarily driven by high unmet clinical needs in refractory cancers, neurodegenerative disorders, heart failure, diabetes, and inherited retinal diseases. iPSCs provide a continuously expandable cell source, enabling a shift from donor-dependent therapies or patient-specific autologous manufacturing toward standardized, scalable, and potentially off-the-shelf cell products. This transition is gradually enabling batch production and inventory-based supply models in cell replacement therapy, immunotherapy, and tissue regeneration.
Product development is concentrated on allogeneic universal donor approaches, HLA-matched cell banks, low-immunogenicity gene-edited cell lines, CAR-iNK/CAR-iT platforms, iPSC-derived islet cells, neural progenitor cells, and cardiomyocyte-based therapies. Competitive differentiation is no longer limited to cell type selection, but increasingly depends on stable differentiation protocols, master cell bank quality, detection of residual undifferentiated cells, potency assays, post-thaw functional recovery, and closed-system GMP scale-up capabilities.
Regional opportunities are concentrated in the United States, Japan, China, and Europe. Japan maintains a first-mover advantage in regenerative medicine regulation and iPSC clinical translation, U.S. companies lead in immune cell engineering and financing strength, while Chinese companies are advancing rapidly in neurological disease clinical development. Key risks include tumorigenicity, immune rejection, long-term patient follow-up requirements, high manufacturing costs, and inconsistency in release standards. Companies capable of simultaneously addressing safety, scalability, and clinically validated efficacy are more likely to secure strategic partnerships and industry adoption.
Report Scope
This report studies the global iPSC-Derived Cell Therapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for iPSC-Derived Cell Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of iPSC-Derived Cell Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global iPSC-Derived Cell Therapy total market, 2021-2032, (USD Million)
Global iPSC-Derived Cell Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: iPSC-Derived Cell Therapy total market, key domestic companies, and share, (USD Million)
Global iPSC-Derived Cell Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
Global iPSC-Derived Cell Therapy total market by Type, CAGR, 2021-2032, (USD Million)
Global iPSC-Derived Cell Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global iPSC-Derived Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Fate Therapeutics, Century Therapeutics, Sumitomo Pharma, BlueRock Therapeutics, Heartseed, Sana Biotechnology, Aspen Neuroscience, iRegene Therapeutics, XellSmart, TreeFrog Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world iPSC-Derived Cell Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global iPSC-Derived Cell Therapy Market, By Region:
1. How big is the global iPSC-Derived Cell Therapy market?
2. What is the demand of the global iPSC-Derived Cell Therapy market?
3. What is the year over year growth of the global iPSC-Derived Cell Therapy market?
4. What is the total value of the global iPSC-Derived Cell Therapy market?
5. Who are the Major Players in the global iPSC-Derived Cell Therapy market?
6. What are the growth factors driving the market demand?
iPSC-Derived Cell Therapy refers to living cell therapeutic products manufactured from induced pluripotent stem cells (iPSCs) through processes including directed differentiation, purification, expansion, genetic engineering, and quality release testing. These products encompass multiple cell types such as NK/T immune cells, neural progenitor cells, cardiomyocytes, pancreatic islet cells, retinal cells, and mesenchymal stromal cells. They are being developed for applications in oncology, Parkinson?s disease, heart failure, diabetes, retinal degenerative diseases, and inflammatory tissue repair. The platform emphasizes lineage consistency, genomic stability, control of residual undifferentiated cells, immune matching strategies, cryopreserved formulation, and clinical-grade GMP scalable manufacturing capabilities. The overall gross margin is approximately 65%.
Demand for iPSC-derived cell therapies is primarily driven by high unmet clinical needs in refractory cancers, neurodegenerative disorders, heart failure, diabetes, and inherited retinal diseases. iPSCs provide a continuously expandable cell source, enabling a shift from donor-dependent therapies or patient-specific autologous manufacturing toward standardized, scalable, and potentially off-the-shelf cell products. This transition is gradually enabling batch production and inventory-based supply models in cell replacement therapy, immunotherapy, and tissue regeneration.
Product development is concentrated on allogeneic universal donor approaches, HLA-matched cell banks, low-immunogenicity gene-edited cell lines, CAR-iNK/CAR-iT platforms, iPSC-derived islet cells, neural progenitor cells, and cardiomyocyte-based therapies. Competitive differentiation is no longer limited to cell type selection, but increasingly depends on stable differentiation protocols, master cell bank quality, detection of residual undifferentiated cells, potency assays, post-thaw functional recovery, and closed-system GMP scale-up capabilities.
Regional opportunities are concentrated in the United States, Japan, China, and Europe. Japan maintains a first-mover advantage in regenerative medicine regulation and iPSC clinical translation, U.S. companies lead in immune cell engineering and financing strength, while Chinese companies are advancing rapidly in neurological disease clinical development. Key risks include tumorigenicity, immune rejection, long-term patient follow-up requirements, high manufacturing costs, and inconsistency in release standards. Companies capable of simultaneously addressing safety, scalability, and clinically validated efficacy are more likely to secure strategic partnerships and industry adoption.
Report Scope
This report studies the global iPSC-Derived Cell Therapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for iPSC-Derived Cell Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of iPSC-Derived Cell Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global iPSC-Derived Cell Therapy total market, 2021-2032, (USD Million)
Global iPSC-Derived Cell Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: iPSC-Derived Cell Therapy total market, key domestic companies, and share, (USD Million)
Global iPSC-Derived Cell Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
Global iPSC-Derived Cell Therapy total market by Type, CAGR, 2021-2032, (USD Million)
Global iPSC-Derived Cell Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global iPSC-Derived Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Fate Therapeutics, Century Therapeutics, Sumitomo Pharma, BlueRock Therapeutics, Heartseed, Sana Biotechnology, Aspen Neuroscience, iRegene Therapeutics, XellSmart, TreeFrog Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world iPSC-Derived Cell Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global iPSC-Derived Cell Therapy Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- iPSC-Derived NK Cell Therapy
- iPSC-Derived T Cell Therapy
- iPSC-Derived Neural Cell Therapy
- iPSC-Derived Cardiomyocyte Therapy
- iPSC-Derived Pancreatic Islet Cell Therapy
- iPSC-Derived Retinal Cell Therapy
- iPSC-Derived Mesenchymal Stromal Cell Therapy
- Other iPSC-Derived Cell Therapy
- Standard Allogeneic Therapy
- HLA-Matched Allogeneic Therapy
- Gene-Edited Hypoimmune Therapy
- Autologous Patient-Specific Therapy
- Other Immune Matching Strategy
- Approved or Conditional Approval
- Phase III or Pivotal Clinical
- Phase II Clinical
- Phase I or I/II Clinical
- Preclinical or IND-Enabling
- Discovery and Research
- Intravenous Systemic Delivery
- Intracerebral or Putaminal Delivery
- Intramyocardial Delivery
- Subretinal or Ocular Delivery
- Intra-Articular Delivery
- Topical or Implantable Dressing
- Other Local Delivery
- Oncology
- Neurological Disorders
- Cardiovascular Diseases
- Diabetes and Metabolic Diseases
- Ophthalmic Diseases
- Other Regenerative and Immune Diseases
- Fate Therapeutics
- Century Therapeutics
- Sumitomo Pharma
- BlueRock Therapeutics
- Heartseed
- Sana Biotechnology
- Aspen Neuroscience
- iRegene Therapeutics
- XellSmart
- TreeFrog Therapeutics
- Cynata Therapeutics
- Shoreline Biosciences
- Evotec
- FUJIFILM Cellular Dynamics
- Opsis Therapeutics
- Cellistic
1. How big is the global iPSC-Derived Cell Therapy market?
2. What is the demand of the global iPSC-Derived Cell Therapy market?
3. What is the year over year growth of the global iPSC-Derived Cell Therapy market?
4. What is the total value of the global iPSC-Derived Cell Therapy market?
5. Who are the Major Players in the global iPSC-Derived Cell Therapy market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 iPSC-Derived Cell Therapy Introduction
1.2 World iPSC-Derived Cell Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World iPSC-Derived Cell Therapy Total Market by Region (by Headquarter Location)
1.3.1 World iPSC-Derived Cell Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.3 China Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.4 Europe Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.5 Japan Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.8 India Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 iPSC-Derived Cell Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.2 World iPSC-Derived Cell Therapy Consumption Value by Region
2.2.1 World iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026)
2.2.2 World iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.4 China iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.5 Europe iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.6 Japan iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.7 South Korea iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.8 ASEAN iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.9 India iPSC-Derived Cell Therapy Consumption Value (2021-2032)
3 WORLD IPSC-DERIVED CELL THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World iPSC-Derived Cell Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global iPSC-Derived Cell Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for iPSC-Derived Cell Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for iPSC-Derived Cell Therapy in 2025
3.3 iPSC-Derived Cell Therapy Company Evaluation Quadrant
3.4 iPSC-Derived Cell Therapy Market: Overall Company Footprint Analysis
3.4.1 iPSC-Derived Cell Therapy Market: Region Footprint
3.4.2 iPSC-Derived Cell Therapy Market: Company Product Type Footprint
3.4.3 iPSC-Derived Cell Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: iPSC-Derived Cell Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: iPSC-Derived Cell Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: iPSC-Derived Cell Therapy Consumption Value Comparison
4.2.1 United States VS China: iPSC-Derived Cell Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026)
4.4 China Based Companies iPSC-Derived Cell Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based iPSC-Derived Cell Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026)
4.5 Rest of World Based iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies iPSC-Derived Cell Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World iPSC-Derived Cell Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 iPSC-Derived NK Cell Therapy
5.2.2 iPSC-Derived T Cell Therapy
5.2.3 iPSC-Derived Neural Cell Therapy
5.2.4 iPSC-Derived Cardiomyocyte Therapy
5.2.5 iPSC-Derived Pancreatic Islet Cell Therapy
5.2.6 iPSC-Derived Retinal Cell Therapy
5.2.7 iPSC-Derived Mesenchymal Stromal Cell Therapy
5.2.8 Other iPSC-Derived Cell Therapy
5.3 Market Segment by Type
5.3.1 World iPSC-Derived Cell Therapy Market Size by Type (2021-2026)
5.3.2 World iPSC-Derived Cell Therapy Market Size by Type (2027-2032)
5.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY IMMUNE MATCHING STRATEGY
6.1 World iPSC-Derived Cell Therapy Market Size Overview by Immune Matching Strategy: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Immune Matching Strategy
6.2.1 Standard Allogeneic Therapy
6.2.2 HLA-Matched Allogeneic Therapy
6.2.3 Gene-Edited Hypoimmune Therapy
6.2.4 Autologous Patient-Specific Therapy
6.2.5 Other Immune Matching Strategy
6.3 Market Segment by Immune Matching Strategy
6.3.1 World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2021-2026)
6.3.2 World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2027-2032)
6.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy (2027-2032)
7 MARKET ANALYSIS BY DEVELOPMENT STAGE
7.1 World iPSC-Derived Cell Therapy Market Size Overview by Development Stage: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Development Stage
7.2.1 Approved or Conditional Approval
7.2.2 Phase III or Pivotal Clinical
7.2.3 Phase II Clinical
7.2.4 Phase I or I/II Clinical
7.2.5 Preclinical or IND-Enabling
7.2.6 Discovery and Research
7.3 Market Segment by Development Stage
7.3.1 World iPSC-Derived Cell Therapy Market Size by Development Stage (2021-2026)
7.3.2 World iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032)
7.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2027-2032)
8 MARKET ANALYSIS BY ADMINISTRATION SITE
8.1 World iPSC-Derived Cell Therapy Market Size Overview by Administration Site: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Administration Site
8.2.1 Intravenous Systemic Delivery
8.2.2 Intracerebral or Putaminal Delivery
8.2.3 Intramyocardial Delivery
8.2.4 Subretinal or Ocular Delivery
8.2.5 Intra-Articular Delivery
8.2.6 Topical or Implantable Dressing
8.2.7 Other Local Delivery
8.3 Market Segment by Administration Site
8.3.1 World iPSC-Derived Cell Therapy Market Size by Administration Site (2021-2026)
8.3.2 World iPSC-Derived Cell Therapy Market Size by Administration Site (2027-2032)
8.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site (2027-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World iPSC-Derived Cell Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Oncology
9.2.2 Neurological Disorders
9.2.3 Cardiovascular Diseases
9.2.4 Diabetes and Metabolic Diseases
9.2.5 Ophthalmic Diseases
9.2.6 Other Regenerative and Immune Diseases
9.3 Market Segment by Application
9.3.1 World iPSC-Derived Cell Therapy Market Size by Application (2021-2026)
9.3.2 World iPSC-Derived Cell Therapy Market Size by Application (2027-2032)
9.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)
10 COMPANY PROFILES
10.1 Fate Therapeutics
10.1.1 Fate Therapeutics Details
10.1.2 Fate Therapeutics Major Business
10.1.3 Fate Therapeutics iPSC-Derived Cell Therapy Product and Services
10.1.4 Fate Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.1.5 Fate Therapeutics Recent Developments/Updates
10.1.6 Fate Therapeutics Competitive Strengths & Weaknesses
10.2 Century Therapeutics
10.2.1 Century Therapeutics Details
10.2.2 Century Therapeutics Major Business
10.2.3 Century Therapeutics iPSC-Derived Cell Therapy Product and Services
10.2.4 Century Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.2.5 Century Therapeutics Recent Developments/Updates
10.2.6 Century Therapeutics Competitive Strengths & Weaknesses
10.3 Sumitomo Pharma
10.3.1 Sumitomo Pharma Details
10.3.2 Sumitomo Pharma Major Business
10.3.3 Sumitomo Pharma iPSC-Derived Cell Therapy Product and Services
10.3.4 Sumitomo Pharma iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.3.5 Sumitomo Pharma Recent Developments/Updates
10.3.6 Sumitomo Pharma Competitive Strengths & Weaknesses
10.4 BlueRock Therapeutics
10.4.1 BlueRock Therapeutics Details
10.4.2 BlueRock Therapeutics Major Business
10.4.3 BlueRock Therapeutics iPSC-Derived Cell Therapy Product and Services
10.4.4 BlueRock Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.4.5 BlueRock Therapeutics Recent Developments/Updates
10.4.6 BlueRock Therapeutics Competitive Strengths & Weaknesses
10.5 Heartseed
10.5.1 Heartseed Details
10.5.2 Heartseed Major Business
10.5.3 Heartseed iPSC-Derived Cell Therapy Product and Services
10.5.4 Heartseed iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.5.5 Heartseed Recent Developments/Updates
10.5.6 Heartseed Competitive Strengths & Weaknesses
10.6 Sana Biotechnology
10.6.1 Sana Biotechnology Details
10.6.2 Sana Biotechnology Major Business
10.6.3 Sana Biotechnology iPSC-Derived Cell Therapy Product and Services
10.6.4 Sana Biotechnology iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.6.5 Sana Biotechnology Recent Developments/Updates
10.6.6 Sana Biotechnology Competitive Strengths & Weaknesses
10.7 Aspen Neuroscience
10.7.1 Aspen Neuroscience Details
10.7.2 Aspen Neuroscience Major Business
10.7.3 Aspen Neuroscience iPSC-Derived Cell Therapy Product and Services
10.7.4 Aspen Neuroscience iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.7.5 Aspen Neuroscience Recent Developments/Updates
10.7.6 Aspen Neuroscience Competitive Strengths & Weaknesses
10.8 iRegene Therapeutics
10.8.1 iRegene Therapeutics Details
10.8.2 iRegene Therapeutics Major Business
10.8.3 iRegene Therapeutics iPSC-Derived Cell Therapy Product and Services
10.8.4 iRegene Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.8.5 iRegene Therapeutics Recent Developments/Updates
10.8.6 iRegene Therapeutics Competitive Strengths & Weaknesses
10.9 XellSmart
10.9.1 XellSmart Details
10.9.2 XellSmart Major Business
10.9.3 XellSmart iPSC-Derived Cell Therapy Product and Services
10.9.4 XellSmart iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.9.5 XellSmart Recent Developments/Updates
10.9.6 XellSmart Competitive Strengths & Weaknesses
10.10 TreeFrog Therapeutics
10.10.1 TreeFrog Therapeutics Details
10.10.2 TreeFrog Therapeutics Major Business
10.10.3 TreeFrog Therapeutics iPSC-Derived Cell Therapy Product and Services
10.10.4 TreeFrog Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.10.5 TreeFrog Therapeutics Recent Developments/Updates
10.10.6 TreeFrog Therapeutics Competitive Strengths & Weaknesses
10.11 Cynata Therapeutics
10.11.1 Cynata Therapeutics Details
10.11.2 Cynata Therapeutics Major Business
10.11.3 Cynata Therapeutics iPSC-Derived Cell Therapy Product and Services
10.11.4 Cynata Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.11.5 Cynata Therapeutics Recent Developments/Updates
10.11.6 Cynata Therapeutics Competitive Strengths & Weaknesses
10.12 Shoreline Biosciences
10.12.1 Shoreline Biosciences Details
10.12.2 Shoreline Biosciences Major Business
10.12.3 Shoreline Biosciences iPSC-Derived Cell Therapy Product and Services
10.12.4 Shoreline Biosciences iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.12.5 Shoreline Biosciences Recent Developments/Updates
10.12.6 Shoreline Biosciences Competitive Strengths & Weaknesses
10.13 Evotec
10.13.1 Evotec Details
10.13.2 Evotec Major Business
10.13.3 Evotec iPSC-Derived Cell Therapy Product and Services
10.13.4 Evotec iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.13.5 Evotec Recent Developments/Updates
10.13.6 Evotec Competitive Strengths & Weaknesses
10.14 FUJIFILM Cellular Dynamics
10.14.1 FUJIFILM Cellular Dynamics Details
10.14.2 FUJIFILM Cellular Dynamics Major Business
10.14.3 FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Product and Services
10.14.4 FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.14.5 FUJIFILM Cellular Dynamics Recent Developments/Updates
10.14.6 FUJIFILM Cellular Dynamics Competitive Strengths & Weaknesses
10.15 Opsis Therapeutics
10.15.1 Opsis Therapeutics Details
10.15.2 Opsis Therapeutics Major Business
10.15.3 Opsis Therapeutics iPSC-Derived Cell Therapy Product and Services
10.15.4 Opsis Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.15.5 Opsis Therapeutics Recent Developments/Updates
10.15.6 Opsis Therapeutics Competitive Strengths & Weaknesses
10.16 Cellistic
10.16.1 Cellistic Details
10.16.2 Cellistic Major Business
10.16.3 Cellistic iPSC-Derived Cell Therapy Product and Services
10.16.4 Cellistic iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.16.5 Cellistic Recent Developments/Updates
10.16.6 Cellistic Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 iPSC-Derived Cell Therapy Industry Chain
11.2 iPSC-Derived Cell Therapy Upstream Analysis
11.3 iPSC-Derived Cell Therapy Midstream Analysis
11.4 iPSC-Derived Cell Therapy Downstream Analysis
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
1.1 iPSC-Derived Cell Therapy Introduction
1.2 World iPSC-Derived Cell Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World iPSC-Derived Cell Therapy Total Market by Region (by Headquarter Location)
1.3.1 World iPSC-Derived Cell Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.3 China Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.4 Europe Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.5 Japan Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.8 India Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 iPSC-Derived Cell Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.2 World iPSC-Derived Cell Therapy Consumption Value by Region
2.2.1 World iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026)
2.2.2 World iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.4 China iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.5 Europe iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.6 Japan iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.7 South Korea iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.8 ASEAN iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.9 India iPSC-Derived Cell Therapy Consumption Value (2021-2032)
3 WORLD IPSC-DERIVED CELL THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World iPSC-Derived Cell Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global iPSC-Derived Cell Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for iPSC-Derived Cell Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for iPSC-Derived Cell Therapy in 2025
3.3 iPSC-Derived Cell Therapy Company Evaluation Quadrant
3.4 iPSC-Derived Cell Therapy Market: Overall Company Footprint Analysis
3.4.1 iPSC-Derived Cell Therapy Market: Region Footprint
3.4.2 iPSC-Derived Cell Therapy Market: Company Product Type Footprint
3.4.3 iPSC-Derived Cell Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: iPSC-Derived Cell Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: iPSC-Derived Cell Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: iPSC-Derived Cell Therapy Consumption Value Comparison
4.2.1 United States VS China: iPSC-Derived Cell Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026)
4.4 China Based Companies iPSC-Derived Cell Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based iPSC-Derived Cell Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026)
4.5 Rest of World Based iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies iPSC-Derived Cell Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World iPSC-Derived Cell Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 iPSC-Derived NK Cell Therapy
5.2.2 iPSC-Derived T Cell Therapy
5.2.3 iPSC-Derived Neural Cell Therapy
5.2.4 iPSC-Derived Cardiomyocyte Therapy
5.2.5 iPSC-Derived Pancreatic Islet Cell Therapy
5.2.6 iPSC-Derived Retinal Cell Therapy
5.2.7 iPSC-Derived Mesenchymal Stromal Cell Therapy
5.2.8 Other iPSC-Derived Cell Therapy
5.3 Market Segment by Type
5.3.1 World iPSC-Derived Cell Therapy Market Size by Type (2021-2026)
5.3.2 World iPSC-Derived Cell Therapy Market Size by Type (2027-2032)
5.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY IMMUNE MATCHING STRATEGY
6.1 World iPSC-Derived Cell Therapy Market Size Overview by Immune Matching Strategy: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Immune Matching Strategy
6.2.1 Standard Allogeneic Therapy
6.2.2 HLA-Matched Allogeneic Therapy
6.2.3 Gene-Edited Hypoimmune Therapy
6.2.4 Autologous Patient-Specific Therapy
6.2.5 Other Immune Matching Strategy
6.3 Market Segment by Immune Matching Strategy
6.3.1 World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2021-2026)
6.3.2 World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2027-2032)
6.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy (2027-2032)
7 MARKET ANALYSIS BY DEVELOPMENT STAGE
7.1 World iPSC-Derived Cell Therapy Market Size Overview by Development Stage: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Development Stage
7.2.1 Approved or Conditional Approval
7.2.2 Phase III or Pivotal Clinical
7.2.3 Phase II Clinical
7.2.4 Phase I or I/II Clinical
7.2.5 Preclinical or IND-Enabling
7.2.6 Discovery and Research
7.3 Market Segment by Development Stage
7.3.1 World iPSC-Derived Cell Therapy Market Size by Development Stage (2021-2026)
7.3.2 World iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032)
7.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2027-2032)
8 MARKET ANALYSIS BY ADMINISTRATION SITE
8.1 World iPSC-Derived Cell Therapy Market Size Overview by Administration Site: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Administration Site
8.2.1 Intravenous Systemic Delivery
8.2.2 Intracerebral or Putaminal Delivery
8.2.3 Intramyocardial Delivery
8.2.4 Subretinal or Ocular Delivery
8.2.5 Intra-Articular Delivery
8.2.6 Topical or Implantable Dressing
8.2.7 Other Local Delivery
8.3 Market Segment by Administration Site
8.3.1 World iPSC-Derived Cell Therapy Market Size by Administration Site (2021-2026)
8.3.2 World iPSC-Derived Cell Therapy Market Size by Administration Site (2027-2032)
8.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site (2027-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World iPSC-Derived Cell Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Oncology
9.2.2 Neurological Disorders
9.2.3 Cardiovascular Diseases
9.2.4 Diabetes and Metabolic Diseases
9.2.5 Ophthalmic Diseases
9.2.6 Other Regenerative and Immune Diseases
9.3 Market Segment by Application
9.3.1 World iPSC-Derived Cell Therapy Market Size by Application (2021-2026)
9.3.2 World iPSC-Derived Cell Therapy Market Size by Application (2027-2032)
9.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)
10 COMPANY PROFILES
10.1 Fate Therapeutics
10.1.1 Fate Therapeutics Details
10.1.2 Fate Therapeutics Major Business
10.1.3 Fate Therapeutics iPSC-Derived Cell Therapy Product and Services
10.1.4 Fate Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.1.5 Fate Therapeutics Recent Developments/Updates
10.1.6 Fate Therapeutics Competitive Strengths & Weaknesses
10.2 Century Therapeutics
10.2.1 Century Therapeutics Details
10.2.2 Century Therapeutics Major Business
10.2.3 Century Therapeutics iPSC-Derived Cell Therapy Product and Services
10.2.4 Century Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.2.5 Century Therapeutics Recent Developments/Updates
10.2.6 Century Therapeutics Competitive Strengths & Weaknesses
10.3 Sumitomo Pharma
10.3.1 Sumitomo Pharma Details
10.3.2 Sumitomo Pharma Major Business
10.3.3 Sumitomo Pharma iPSC-Derived Cell Therapy Product and Services
10.3.4 Sumitomo Pharma iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.3.5 Sumitomo Pharma Recent Developments/Updates
10.3.6 Sumitomo Pharma Competitive Strengths & Weaknesses
10.4 BlueRock Therapeutics
10.4.1 BlueRock Therapeutics Details
10.4.2 BlueRock Therapeutics Major Business
10.4.3 BlueRock Therapeutics iPSC-Derived Cell Therapy Product and Services
10.4.4 BlueRock Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.4.5 BlueRock Therapeutics Recent Developments/Updates
10.4.6 BlueRock Therapeutics Competitive Strengths & Weaknesses
10.5 Heartseed
10.5.1 Heartseed Details
10.5.2 Heartseed Major Business
10.5.3 Heartseed iPSC-Derived Cell Therapy Product and Services
10.5.4 Heartseed iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.5.5 Heartseed Recent Developments/Updates
10.5.6 Heartseed Competitive Strengths & Weaknesses
10.6 Sana Biotechnology
10.6.1 Sana Biotechnology Details
10.6.2 Sana Biotechnology Major Business
10.6.3 Sana Biotechnology iPSC-Derived Cell Therapy Product and Services
10.6.4 Sana Biotechnology iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.6.5 Sana Biotechnology Recent Developments/Updates
10.6.6 Sana Biotechnology Competitive Strengths & Weaknesses
10.7 Aspen Neuroscience
10.7.1 Aspen Neuroscience Details
10.7.2 Aspen Neuroscience Major Business
10.7.3 Aspen Neuroscience iPSC-Derived Cell Therapy Product and Services
10.7.4 Aspen Neuroscience iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.7.5 Aspen Neuroscience Recent Developments/Updates
10.7.6 Aspen Neuroscience Competitive Strengths & Weaknesses
10.8 iRegene Therapeutics
10.8.1 iRegene Therapeutics Details
10.8.2 iRegene Therapeutics Major Business
10.8.3 iRegene Therapeutics iPSC-Derived Cell Therapy Product and Services
10.8.4 iRegene Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.8.5 iRegene Therapeutics Recent Developments/Updates
10.8.6 iRegene Therapeutics Competitive Strengths & Weaknesses
10.9 XellSmart
10.9.1 XellSmart Details
10.9.2 XellSmart Major Business
10.9.3 XellSmart iPSC-Derived Cell Therapy Product and Services
10.9.4 XellSmart iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.9.5 XellSmart Recent Developments/Updates
10.9.6 XellSmart Competitive Strengths & Weaknesses
10.10 TreeFrog Therapeutics
10.10.1 TreeFrog Therapeutics Details
10.10.2 TreeFrog Therapeutics Major Business
10.10.3 TreeFrog Therapeutics iPSC-Derived Cell Therapy Product and Services
10.10.4 TreeFrog Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.10.5 TreeFrog Therapeutics Recent Developments/Updates
10.10.6 TreeFrog Therapeutics Competitive Strengths & Weaknesses
10.11 Cynata Therapeutics
10.11.1 Cynata Therapeutics Details
10.11.2 Cynata Therapeutics Major Business
10.11.3 Cynata Therapeutics iPSC-Derived Cell Therapy Product and Services
10.11.4 Cynata Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.11.5 Cynata Therapeutics Recent Developments/Updates
10.11.6 Cynata Therapeutics Competitive Strengths & Weaknesses
10.12 Shoreline Biosciences
10.12.1 Shoreline Biosciences Details
10.12.2 Shoreline Biosciences Major Business
10.12.3 Shoreline Biosciences iPSC-Derived Cell Therapy Product and Services
10.12.4 Shoreline Biosciences iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.12.5 Shoreline Biosciences Recent Developments/Updates
10.12.6 Shoreline Biosciences Competitive Strengths & Weaknesses
10.13 Evotec
10.13.1 Evotec Details
10.13.2 Evotec Major Business
10.13.3 Evotec iPSC-Derived Cell Therapy Product and Services
10.13.4 Evotec iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.13.5 Evotec Recent Developments/Updates
10.13.6 Evotec Competitive Strengths & Weaknesses
10.14 FUJIFILM Cellular Dynamics
10.14.1 FUJIFILM Cellular Dynamics Details
10.14.2 FUJIFILM Cellular Dynamics Major Business
10.14.3 FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Product and Services
10.14.4 FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.14.5 FUJIFILM Cellular Dynamics Recent Developments/Updates
10.14.6 FUJIFILM Cellular Dynamics Competitive Strengths & Weaknesses
10.15 Opsis Therapeutics
10.15.1 Opsis Therapeutics Details
10.15.2 Opsis Therapeutics Major Business
10.15.3 Opsis Therapeutics iPSC-Derived Cell Therapy Product and Services
10.15.4 Opsis Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.15.5 Opsis Therapeutics Recent Developments/Updates
10.15.6 Opsis Therapeutics Competitive Strengths & Weaknesses
10.16 Cellistic
10.16.1 Cellistic Details
10.16.2 Cellistic Major Business
10.16.3 Cellistic iPSC-Derived Cell Therapy Product and Services
10.16.4 Cellistic iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.16.5 Cellistic Recent Developments/Updates
10.16.6 Cellistic Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 iPSC-Derived Cell Therapy Industry Chain
11.2 iPSC-Derived Cell Therapy Upstream Analysis
11.3 iPSC-Derived Cell Therapy Midstream Analysis
11.4 iPSC-Derived Cell Therapy Downstream Analysis
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
LIST OF TABLES
Table 1. World iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World iPSC-Derived Cell Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World iPSC-Derived Cell Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World iPSC-Derived Cell Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World iPSC-Derived Cell Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key iPSC-Derived Cell Therapy Players in 2025
Table 12. World iPSC-Derived Cell Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global iPSC-Derived Cell Therapy Company Evaluation Quadrant
Table 14. Head Office of Key iPSC-Derived Cell Therapy Players
Table 15. iPSC-Derived Cell Therapy Market: Company Product Type Footprint
Table 16. iPSC-Derived Cell Therapy Market: Company Product Application Footprint
Table 17. iPSC-Derived Cell Therapy Mergers & Acquisitions Activity
Table 18. United States VS China iPSC-Derived Cell Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China iPSC-Derived Cell Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 23. China Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies iPSC-Derived Cell Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 29. World iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World iPSC-Derived Cell Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World iPSC-Derived Cell Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy, (USD Million), 2021 & 2025 & 2032
Table 33. World iPSC-Derived Cell Therapy Market Size Value by Immune Matching Strategy (2021-2026) & (USD Million)
Table 34. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2027-2032) & (USD Million)
Table 35. World iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032
Table 36. World iPSC-Derived Cell Therapy Market Size Value by Development Stage (2021-2026) & (USD Million)
Table 37. World iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032) & (USD Million)
Table 38. World iPSC-Derived Cell Therapy Market Size by Administration Site, (USD Million), 2021 & 2025 & 2032
Table 39. World iPSC-Derived Cell Therapy Market Size Value by Administration Site (2021-2026) & (USD Million)
Table 40. World iPSC-Derived Cell Therapy Market Size by Administration Site (2027-2032) & (USD Million)
Table 41. World iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 42. World iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (USD Million)
Table 43. World iPSC-Derived Cell Therapy Market Size by Application (2027-2032) & (USD Million)
Table 44. Fate Therapeutics Basic Information, Manufacturing Base and Competitors
Table 45. Fate Therapeutics Major Business
Table 46. Fate Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 47. Fate Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Fate Therapeutics Recent Developments/Updates
Table 49. Fate Therapeutics Competitive Strengths & Weaknesses
Table 50. Century Therapeutics Basic Information, Manufacturing Base and Competitors
Table 51. Century Therapeutics Major Business
Table 52. Century Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 53. Century Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Century Therapeutics Recent Developments/Updates
Table 55. Century Therapeutics Competitive Strengths & Weaknesses
Table 56. Sumitomo Pharma Basic Information, Manufacturing Base and Competitors
Table 57. Sumitomo Pharma Major Business
Table 58. Sumitomo Pharma iPSC-Derived Cell Therapy Product and Services
Table 59. Sumitomo Pharma iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Sumitomo Pharma Recent Developments/Updates
Table 61. Sumitomo Pharma Competitive Strengths & Weaknesses
Table 62. BlueRock Therapeutics Basic Information, Manufacturing Base and Competitors
Table 63. BlueRock Therapeutics Major Business
Table 64. BlueRock Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 65. BlueRock Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. BlueRock Therapeutics Recent Developments/Updates
Table 67. BlueRock Therapeutics Competitive Strengths & Weaknesses
Table 68. Heartseed Basic Information, Manufacturing Base and Competitors
Table 69. Heartseed Major Business
Table 70. Heartseed iPSC-Derived Cell Therapy Product and Services
Table 71. Heartseed iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Heartseed Recent Developments/Updates
Table 73. Heartseed Competitive Strengths & Weaknesses
Table 74. Sana Biotechnology Basic Information, Manufacturing Base and Competitors
Table 75. Sana Biotechnology Major Business
Table 76. Sana Biotechnology iPSC-Derived Cell Therapy Product and Services
Table 77. Sana Biotechnology iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Sana Biotechnology Recent Developments/Updates
Table 79. Sana Biotechnology Competitive Strengths & Weaknesses
Table 80. Aspen Neuroscience Basic Information, Manufacturing Base and Competitors
Table 81. Aspen Neuroscience Major Business
Table 82. Aspen Neuroscience iPSC-Derived Cell Therapy Product and Services
Table 83. Aspen Neuroscience iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Aspen Neuroscience Recent Developments/Updates
Table 85. Aspen Neuroscience Competitive Strengths & Weaknesses
Table 86. iRegene Therapeutics Basic Information, Manufacturing Base and Competitors
Table 87. iRegene Therapeutics Major Business
Table 88. iRegene Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 89. iRegene Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. iRegene Therapeutics Recent Developments/Updates
Table 91. iRegene Therapeutics Competitive Strengths & Weaknesses
Table 92. XellSmart Basic Information, Manufacturing Base and Competitors
Table 93. XellSmart Major Business
Table 94. XellSmart iPSC-Derived Cell Therapy Product and Services
Table 95. XellSmart iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. XellSmart Recent Developments/Updates
Table 97. XellSmart Competitive Strengths & Weaknesses
Table 98. TreeFrog Therapeutics Basic Information, Manufacturing Base and Competitors
Table 99. TreeFrog Therapeutics Major Business
Table 100. TreeFrog Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 101. TreeFrog Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 102. TreeFrog Therapeutics Recent Developments/Updates
Table 103. TreeFrog Therapeutics Competitive Strengths & Weaknesses
Table 104. Cynata Therapeutics Basic Information, Manufacturing Base and Competitors
Table 105. Cynata Therapeutics Major Business
Table 106. Cynata Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 107. Cynata Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. Cynata Therapeutics Recent Developments/Updates
Table 109. Cynata Therapeutics Competitive Strengths & Weaknesses
Table 110. Shoreline Biosciences Basic Information, Manufacturing Base and Competitors
Table 111. Shoreline Biosciences Major Business
Table 112. Shoreline Biosciences iPSC-Derived Cell Therapy Product and Services
Table 113. Shoreline Biosciences iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. Shoreline Biosciences Recent Developments/Updates
Table 115. Shoreline Biosciences Competitive Strengths & Weaknesses
Table 116. Evotec Basic Information, Manufacturing Base and Competitors
Table 117. Evotec Major Business
Table 118. Evotec iPSC-Derived Cell Therapy Product and Services
Table 119. Evotec iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Evotec Recent Developments/Updates
Table 121. Evotec Competitive Strengths & Weaknesses
Table 122. FUJIFILM Cellular Dynamics Basic Information, Manufacturing Base and Competitors
Table 123. FUJIFILM Cellular Dynamics Major Business
Table 124. FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Product and Services
Table 125. FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. FUJIFILM Cellular Dynamics Recent Developments/Updates
Table 127. FUJIFILM Cellular Dynamics Competitive Strengths & Weaknesses
Table 128. Opsis Therapeutics Basic Information, Manufacturing Base and Competitors
Table 129. Opsis Therapeutics Major Business
Table 130. Opsis Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 131. Opsis Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Opsis Therapeutics Recent Developments/Updates
Table 133. Opsis Therapeutics Competitive Strengths & Weaknesses
Table 134. Cellistic Basic Information, Manufacturing Base and Competitors
Table 135. Cellistic Major Business
Table 136. Cellistic iPSC-Derived Cell Therapy Product and Services
Table 137. Cellistic iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 138. Cellistic Recent Developments/Updates
Table 139. Cellistic Competitive Strengths & Weaknesses
Table 140. Global Key Players of iPSC-Derived Cell Therapy Upstream (Raw Materials)
Table 141. Global iPSC-Derived Cell Therapy Typical Customers
Table 1. World iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World iPSC-Derived Cell Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World iPSC-Derived Cell Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World iPSC-Derived Cell Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World iPSC-Derived Cell Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key iPSC-Derived Cell Therapy Players in 2025
Table 12. World iPSC-Derived Cell Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global iPSC-Derived Cell Therapy Company Evaluation Quadrant
Table 14. Head Office of Key iPSC-Derived Cell Therapy Players
Table 15. iPSC-Derived Cell Therapy Market: Company Product Type Footprint
Table 16. iPSC-Derived Cell Therapy Market: Company Product Application Footprint
Table 17. iPSC-Derived Cell Therapy Mergers & Acquisitions Activity
Table 18. United States VS China iPSC-Derived Cell Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China iPSC-Derived Cell Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 23. China Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies iPSC-Derived Cell Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 29. World iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World iPSC-Derived Cell Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World iPSC-Derived Cell Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy, (USD Million), 2021 & 2025 & 2032
Table 33. World iPSC-Derived Cell Therapy Market Size Value by Immune Matching Strategy (2021-2026) & (USD Million)
Table 34. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2027-2032) & (USD Million)
Table 35. World iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032
Table 36. World iPSC-Derived Cell Therapy Market Size Value by Development Stage (2021-2026) & (USD Million)
Table 37. World iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032) & (USD Million)
Table 38. World iPSC-Derived Cell Therapy Market Size by Administration Site, (USD Million), 2021 & 2025 & 2032
Table 39. World iPSC-Derived Cell Therapy Market Size Value by Administration Site (2021-2026) & (USD Million)
Table 40. World iPSC-Derived Cell Therapy Market Size by Administration Site (2027-2032) & (USD Million)
Table 41. World iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 42. World iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (USD Million)
Table 43. World iPSC-Derived Cell Therapy Market Size by Application (2027-2032) & (USD Million)
Table 44. Fate Therapeutics Basic Information, Manufacturing Base and Competitors
Table 45. Fate Therapeutics Major Business
Table 46. Fate Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 47. Fate Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Fate Therapeutics Recent Developments/Updates
Table 49. Fate Therapeutics Competitive Strengths & Weaknesses
Table 50. Century Therapeutics Basic Information, Manufacturing Base and Competitors
Table 51. Century Therapeutics Major Business
Table 52. Century Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 53. Century Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Century Therapeutics Recent Developments/Updates
Table 55. Century Therapeutics Competitive Strengths & Weaknesses
Table 56. Sumitomo Pharma Basic Information, Manufacturing Base and Competitors
Table 57. Sumitomo Pharma Major Business
Table 58. Sumitomo Pharma iPSC-Derived Cell Therapy Product and Services
Table 59. Sumitomo Pharma iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Sumitomo Pharma Recent Developments/Updates
Table 61. Sumitomo Pharma Competitive Strengths & Weaknesses
Table 62. BlueRock Therapeutics Basic Information, Manufacturing Base and Competitors
Table 63. BlueRock Therapeutics Major Business
Table 64. BlueRock Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 65. BlueRock Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. BlueRock Therapeutics Recent Developments/Updates
Table 67. BlueRock Therapeutics Competitive Strengths & Weaknesses
Table 68. Heartseed Basic Information, Manufacturing Base and Competitors
Table 69. Heartseed Major Business
Table 70. Heartseed iPSC-Derived Cell Therapy Product and Services
Table 71. Heartseed iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Heartseed Recent Developments/Updates
Table 73. Heartseed Competitive Strengths & Weaknesses
Table 74. Sana Biotechnology Basic Information, Manufacturing Base and Competitors
Table 75. Sana Biotechnology Major Business
Table 76. Sana Biotechnology iPSC-Derived Cell Therapy Product and Services
Table 77. Sana Biotechnology iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Sana Biotechnology Recent Developments/Updates
Table 79. Sana Biotechnology Competitive Strengths & Weaknesses
Table 80. Aspen Neuroscience Basic Information, Manufacturing Base and Competitors
Table 81. Aspen Neuroscience Major Business
Table 82. Aspen Neuroscience iPSC-Derived Cell Therapy Product and Services
Table 83. Aspen Neuroscience iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Aspen Neuroscience Recent Developments/Updates
Table 85. Aspen Neuroscience Competitive Strengths & Weaknesses
Table 86. iRegene Therapeutics Basic Information, Manufacturing Base and Competitors
Table 87. iRegene Therapeutics Major Business
Table 88. iRegene Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 89. iRegene Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. iRegene Therapeutics Recent Developments/Updates
Table 91. iRegene Therapeutics Competitive Strengths & Weaknesses
Table 92. XellSmart Basic Information, Manufacturing Base and Competitors
Table 93. XellSmart Major Business
Table 94. XellSmart iPSC-Derived Cell Therapy Product and Services
Table 95. XellSmart iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. XellSmart Recent Developments/Updates
Table 97. XellSmart Competitive Strengths & Weaknesses
Table 98. TreeFrog Therapeutics Basic Information, Manufacturing Base and Competitors
Table 99. TreeFrog Therapeutics Major Business
Table 100. TreeFrog Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 101. TreeFrog Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 102. TreeFrog Therapeutics Recent Developments/Updates
Table 103. TreeFrog Therapeutics Competitive Strengths & Weaknesses
Table 104. Cynata Therapeutics Basic Information, Manufacturing Base and Competitors
Table 105. Cynata Therapeutics Major Business
Table 106. Cynata Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 107. Cynata Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. Cynata Therapeutics Recent Developments/Updates
Table 109. Cynata Therapeutics Competitive Strengths & Weaknesses
Table 110. Shoreline Biosciences Basic Information, Manufacturing Base and Competitors
Table 111. Shoreline Biosciences Major Business
Table 112. Shoreline Biosciences iPSC-Derived Cell Therapy Product and Services
Table 113. Shoreline Biosciences iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. Shoreline Biosciences Recent Developments/Updates
Table 115. Shoreline Biosciences Competitive Strengths & Weaknesses
Table 116. Evotec Basic Information, Manufacturing Base and Competitors
Table 117. Evotec Major Business
Table 118. Evotec iPSC-Derived Cell Therapy Product and Services
Table 119. Evotec iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Evotec Recent Developments/Updates
Table 121. Evotec Competitive Strengths & Weaknesses
Table 122. FUJIFILM Cellular Dynamics Basic Information, Manufacturing Base and Competitors
Table 123. FUJIFILM Cellular Dynamics Major Business
Table 124. FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Product and Services
Table 125. FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. FUJIFILM Cellular Dynamics Recent Developments/Updates
Table 127. FUJIFILM Cellular Dynamics Competitive Strengths & Weaknesses
Table 128. Opsis Therapeutics Basic Information, Manufacturing Base and Competitors
Table 129. Opsis Therapeutics Major Business
Table 130. Opsis Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 131. Opsis Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Opsis Therapeutics Recent Developments/Updates
Table 133. Opsis Therapeutics Competitive Strengths & Weaknesses
Table 134. Cellistic Basic Information, Manufacturing Base and Competitors
Table 135. Cellistic Major Business
Table 136. Cellistic iPSC-Derived Cell Therapy Product and Services
Table 137. Cellistic iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 138. Cellistic Recent Developments/Updates
Table 139. Cellistic Competitive Strengths & Weaknesses
Table 140. Global Key Players of iPSC-Derived Cell Therapy Upstream (Raw Materials)
Table 141. Global iPSC-Derived Cell Therapy Typical Customers
LIST OF FIGURES
Figure 1. iPSC-Derived Cell Therapy Picture
Figure 2. World iPSC-Derived Cell Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World iPSC-Derived Cell Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 13. iPSC-Derived Cell Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World iPSC-Derived Cell Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of iPSC-Derived Cell Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for iPSC-Derived Cell Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for iPSC-Derived Cell Therapy Markets in 2025
Figure 27. United States VS China: iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World iPSC-Derived Cell Therapy Market Size Market Share by Type in 2025
Figure 31. iPSC-Derived NK Cell Therapy
Figure 32. iPSC-Derived T Cell Therapy
Figure 33. iPSC-Derived Neural Cell Therapy
Figure 34. iPSC-Derived Cardiomyocyte Therapy
Figure 35. iPSC-Derived Pancreatic Islet Cell Therapy
Figure 36. iPSC-Derived Retinal Cell Therapy
Figure 37. iPSC-Derived Mesenchymal Stromal Cell Therapy
Figure 38. Other iPSC-Derived Cell Therapy
Figure 39. iPSC-Derived Mesenchymal Stromal Cell Therapy
Figure 40. World iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2032)
Figure 41. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy, (USD Million), 2021 & 2025 & 2032
Figure 42. World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy in 2025
Figure 43. Standard Allogeneic Therapy
Figure 44. HLA-Matched Allogeneic Therapy
Figure 45. Gene-Edited Hypoimmune Therapy
Figure 46. Autologous Patient-Specific Therapy
Figure 47. Other Immune Matching Strategy
Figure 48. World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy (2021-2032)
Figure 49. World iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032
Figure 50. World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage in 2025
Figure 51. Approved or Conditional Approval
Figure 52. Phase III or Pivotal Clinical
Figure 53. Phase II Clinical
Figure 54. Phase I or I/II Clinical
Figure 55. Preclinical or IND-Enabling
Figure 56. Discovery and Research
Figure 57. World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2021-2032)
Figure 58. World iPSC-Derived Cell Therapy Market Size by Administration Site, (USD Million), 2021 & 2025 & 2032
Figure 59. World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site in 2025
Figure 60. Intravenous Systemic Delivery
Figure 61. Intracerebral or Putaminal Delivery
Figure 62. Intramyocardial Delivery
Figure 63. Subretinal or Ocular Delivery
Figure 64. Intra-Articular Delivery
Figure 65. Topical or Implantable Dressing
Figure 66. Other Local Delivery
Figure 67. Other Local Delivery
Figure 68. World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site (2021-2032)
Figure 69. World iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 70. World iPSC-Derived Cell Therapy Market Size Market Share by Application in 2025
Figure 71. Oncology
Figure 72. Neurological Disorders
Figure 73. Cardiovascular Diseases
Figure 74. Diabetes and Metabolic Diseases
Figure 75. Ophthalmic Diseases
Figure 76. Other Regenerative and Immune Diseases
Figure 77. World iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)
Figure 78. iPSC-Derived Cell Therapy Industrial Chain
Figure 79. Methodology
Figure 80. Research Process and Data Source
Figure 1. iPSC-Derived Cell Therapy Picture
Figure 2. World iPSC-Derived Cell Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World iPSC-Derived Cell Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 13. iPSC-Derived Cell Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World iPSC-Derived Cell Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of iPSC-Derived Cell Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for iPSC-Derived Cell Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for iPSC-Derived Cell Therapy Markets in 2025
Figure 27. United States VS China: iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World iPSC-Derived Cell Therapy Market Size Market Share by Type in 2025
Figure 31. iPSC-Derived NK Cell Therapy
Figure 32. iPSC-Derived T Cell Therapy
Figure 33. iPSC-Derived Neural Cell Therapy
Figure 34. iPSC-Derived Cardiomyocyte Therapy
Figure 35. iPSC-Derived Pancreatic Islet Cell Therapy
Figure 36. iPSC-Derived Retinal Cell Therapy
Figure 37. iPSC-Derived Mesenchymal Stromal Cell Therapy
Figure 38. Other iPSC-Derived Cell Therapy
Figure 39. iPSC-Derived Mesenchymal Stromal Cell Therapy
Figure 40. World iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2032)
Figure 41. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy, (USD Million), 2021 & 2025 & 2032
Figure 42. World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy in 2025
Figure 43. Standard Allogeneic Therapy
Figure 44. HLA-Matched Allogeneic Therapy
Figure 45. Gene-Edited Hypoimmune Therapy
Figure 46. Autologous Patient-Specific Therapy
Figure 47. Other Immune Matching Strategy
Figure 48. World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy (2021-2032)
Figure 49. World iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032
Figure 50. World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage in 2025
Figure 51. Approved or Conditional Approval
Figure 52. Phase III or Pivotal Clinical
Figure 53. Phase II Clinical
Figure 54. Phase I or I/II Clinical
Figure 55. Preclinical or IND-Enabling
Figure 56. Discovery and Research
Figure 57. World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2021-2032)
Figure 58. World iPSC-Derived Cell Therapy Market Size by Administration Site, (USD Million), 2021 & 2025 & 2032
Figure 59. World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site in 2025
Figure 60. Intravenous Systemic Delivery
Figure 61. Intracerebral or Putaminal Delivery
Figure 62. Intramyocardial Delivery
Figure 63. Subretinal or Ocular Delivery
Figure 64. Intra-Articular Delivery
Figure 65. Topical or Implantable Dressing
Figure 66. Other Local Delivery
Figure 67. Other Local Delivery
Figure 68. World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site (2021-2032)
Figure 69. World iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 70. World iPSC-Derived Cell Therapy Market Size Market Share by Application in 2025
Figure 71. Oncology
Figure 72. Neurological Disorders
Figure 73. Cardiovascular Diseases
Figure 74. Diabetes and Metabolic Diseases
Figure 75. Ophthalmic Diseases
Figure 76. Other Regenerative and Immune Diseases
Figure 77. World iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)
Figure 78. iPSC-Derived Cell Therapy Industrial Chain
Figure 79. Methodology
Figure 80. Research Process and Data Source
